STING1 and neoplasm: Prolonged activation of STING can result in a tolerogenic immune response, chronic neuroinflammation, increased tumour growth and impaired T-lymphocyte function all of which are detrimental in cancer treatment (Huang et al., 2013; Ahn et al., 2014; Larkin et al., 2017; Lemos et al., 2020).